Blueprint Medicines Corp

Blueprint Medicines — AACR Annual Meeting 2021

26 slides from Blueprint Medicines's conference presentation, Apr 12, 2021

  1. Slide 1: Celebrating our first decade of innovation in precision medicine

    Slide 1: Celebrating our first decade of innovation in precision medicine

    Celebrating our first decade of innovation in precision medicine Advancing our next wave of precision therapies to patients APRIL 12, 2021 AACR Annual Meeting 2021 © 2021 Blueprint Medicines Corporation

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "

  3. Slide 3: Blueprint Medicines call participants

    Slide 3: Blueprint Medicines call participants

    Blueprint Medicines call participants Celebrating 10 years of innovation in precision medicine Jeff Albers, Chief Executive Officer AACR 2021 review Fouad Namouni, MD, President, R&D Our plan to transform the treatment of EGFRm NSCLC Selective CDK2 inhibition: a promising therapeutic strategy Becker

  4. Slide 4: Our first decade of precision therapy innovation

    Slide 4: Our first decade of precision therapy innovation

    Our first decade of precision therapy innovation 4 ❖ First to achieve FDA approval of two internally discovered medicines within 10 years ❖ 9 approved or investigational precision therapies1, plus multiple additional undisclosed research programs ❖ 5 FDA breakthrough therapy designations ❖ Global co

  5. Slide 5: Extraordinary research productivity

    Slide 5: Extraordinary research productivity

    Extraordinary research productivity KIT, KIT proto-oncogene receptor kinase; MAP4K1, hematopoietic progenitor kinase 1; SM, systemic mastocytosis. 5 Program Target Therapeutic area focus Trial Planned initiation BLU-263 KIT D816V Non-advanced SM Phase 2/3 Mid 2021 BLU-945 EGFR triple mutant EGFRm NS

  6. Slide 6: Increasingly significant opportunities to impact patients across our portfolio

    Slide 6: Increasingly significant opportunities to impact patients across our portfolio

    Increasingly significant opportunities to impact patients across our portfolio Figure is illustrative. 6 RET KIT D816V EGFR CDK2 MAP4K1 GAVRETOAYVAKIT BLU-263 BLU-701 BLU-945 BLU-222 BLU-852 HEMATOLOGY PRECISION ONCOLOGY IMMUNOTHERAPY Not for promotional use.

  7. Slide 7: AACR 2021 review; Our plan to transform treatment of EGFRm NSCLC

    Slide 7: AACR 2021 review; Our plan to transform treatment of EGFRm NSCLC

    Celebrating our first decade of innovation in precision medicine AACR 2021 review Our plan to transform treatment of EGFRm NSCLC Fouad Namouni, MD President, Research & Development

  8. Slide 8: Interim analysis from PATHFINDER trial of AYVAKIT in advanced SM

    Slide 8: Interim analysis from PATHFINDER trial of AYVAKIT in advanced SM

    Interim analysis from PATHFINDER trial of AYAVKIT in advanced SM Data presented at AACR 2021 Annual Meeting. Data cut-off: June 23, 2020. 1. ORR defined as complete remission with full or partial recovery of peripheral blood counts, partial remission or clinical improvement. ASM, aggressive SM; CI,

  9. Slide 9: Results from a Phase 1 trial of BLU-263 in healthy volunteers

    Slide 9: Results from a Phase 1 trial of BLU-263 in healthy volunteers

    Results from a Phase 1 trial of BLU-263 in healthy volunteers Data presented at AACR 2021 Annual Meeting. Data cut-off: November 9, 2020. AE, adverse event; TRAE, treatment-related AE. 9 • BLU-263 was generally well-tolerated at all doses tested in healthy volunteers • Pharmacokinetics were linear a

  10. Slide 10: Significant patient needs remain in EGFRm NSCLC across all lines of therapies

    Slide 10: Significant patient needs remain in EGFRm NSCLC across all lines of therapies

    Significant patient needs remain in EGFRm NSCLC across all lines of therapies 1. Piper-Vallillo, et al. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib. Journal of Clinical Oncology, 2020. 2. Remon and Besse. Brain metastases in oncogene-addicted NSCLC patients:

  11. Slide 11: BLU-701: potential best-in-class coverage of activating EGFR mutations

    Slide 11: BLU-701: potential best-in-class coverage of activating EGFR mutations

    BLU-701: potential best-in-class coverage of activating EGFR mutations, plus C797S osimertinib-resistant mutants Data presented at AACR 2021 Annual Meeting. 1. Cellular inhibition IC50 (nM) in Ba/F3 cell lines. 2. Cellular inhibition IC50 in A431 (wild-type EGFR) cell line. Wild- type EGFR selectivi

  12. Slide 12: BLU-701 plasma and brain concentrations comparable in preclinical models

    Slide 12: BLU-701 plasma and brain concentrations comparable in preclinical models

    BLU-701 plasma and brain concentrations are comparable in preclinical models, suggesting significant brain penetration Data presented at AACR 2021 Annual Meeting. 12 Compound IV infusion Kpu,u (Css)a BLU-701 0.98 Gefitinib 0.11 Osimertinib 0.30 Not for promotional use. Concentration (ng/mL or ng/g)

  13. Slide 13: BLU-945: potential first-in-class triple-mutant EGFR inhibitor

    Slide 13: BLU-945: potential first-in-class triple-mutant EGFR inhibitor

    BLU-945: potential first-in-class triple-mutant EGFR inhibitor, with exceptional wild-type EGFR selectivity to enable combinations Data presented at AACR 2021 Annual Meeting. 1. Cellular inhibition IC50 (nM) in NCI-H1975 (EGFR double mutant) and Ba/F3 (EGFR triple mutant) cell lines. 2. Cellular inh

  14. Slide 14: BLU-701 and BLU-945 provide comprehensive EGFR mutational coverage

    Slide 14: BLU-701 and BLU-945 provide comprehensive EGFR mutational coverage

    BLU-701 and BLU-945 provide comprehensive EGFR mutational coverage * Based on biochemical IC50. 1L, first line; 2L, second line; 3L, third line; 4G, fourth generation. 14 1G 3G 4G Potential Combinations EGFR mutational coverage* Gefitinib Osimertinib BLU-701 BLU-945 BLU-701 + osimertinib BLU-945 + o

  15. Slide 15: Transforming EGFRm NSCLC treatment with 4G inhibitors

    Slide 15: Transforming EGFRm NSCLC treatment with 4G inhibitors

    We aim to transform EGFRm NSCLC treatment with 4G inhibitors that overcome or prevent on-target resistance across treatment lines 15 FIRST-LINESECOND-LINETHIRD-LINE 3G (osimertinib) BLU-701 BLU-701 + BLU-945 or 3G BLU-701 + RET, MET, KRAS BLU-945 BLU-945 + BLU-701 or 3G 3G (osimertinib) 1G (erlotini

  16. Slide 16: Plan to rapidly develop BLU-945 and BLU-701 monotherapy and combinations

    Slide 16: Plan to rapidly develop BLU-945 and BLU-701 monotherapy and combinations

    Plan to rapidly develop BLU-945 and BLU-701 monotherapy and combination regimens IND, investigational new drug application; RP2D, recommended Part 2 dose. 16 BLU-945 IND APPLICATION CLEARED BY U.S.FDA Dose escalation RP2D 3L monotherapy Combination with 3G inhibitor Dose escalation RP2D 2L monothera

  17. Slide 17: Selective CDK2 inhibition: a promising therapeutic strategy

    Slide 17: Selective CDK2 inhibition: a promising therapeutic strategy

    Celebrating our first decade of innovation in precision medicine Selective CDK2 inhibition: a promising therapeutic strategy for cyclin E aberrant cancers Becker Hewes, MD Chief Medical Officer

  18. Slide 18: BLU-852, first candidate under Roche immunotherapy collaboration

    Slide 18: BLU-852, first candidate under Roche immunotherapy collaboration

    Compound Enzyme activities IC50 (nM) Cell activity IC50 or EC50 (nM) Whole Blood activity IC50 or EC50 (nM) Selectivity MAP4K1 LCK MAP4K4 pSLP76* IL-2† pSLP76* IL-2†% kinome >100x BLU2069 0.17 19 45 29 16 615 517 95% BLU6348 0.13 78 73 27 11 1033 1194 96% BLU-852 0.11 502 1196 40 11 851 1240 97% ANT

  19. Slide 19: Aberrant cyclin E unleashes cellular proliferation

    Slide 19: Aberrant cyclin E unleashes cellular proliferation

    Aberrant cyclin E unleashes cellular proliferation CDK4/6 Cyclin D CDK2 Cyclin E CDK2 Cyclin A CDK1 Cyclin A/B M G1 S G2 CDK-CYCLIN COMPLEXES REGULATE THE CELL CYCLE ABERRANT CYCLIN E (CCNE) DRIVES PROLIFERATION E2Fs HEALTHY CELL REGULATION Rb CANCER CELL PROLIFERATION Rb E2Fs P Aberrant CCNE hypera

  20. Slide 20: Aberrant CCNE is a disease driver in multiple cancers

    Slide 20: Aberrant CCNE is a disease driver in multiple cancers

    Aberrant CCNE is a disease driver in multiple cancers CCNE1 amplification frequency represented as percentage of total patient samples. Data from the National Cancer Institute’s The Cancer Genome Atlas Program (www.cancer.gov/tcga). 20 0% 10% 20% 30% 40% Breast invasive carcinoma Lung adenocarcinoma

  21. Slide 21: Aberrant CCNE is associated with poor disease outcomes

    Slide 21: Aberrant CCNE is associated with poor disease outcomes

    Aberrant CCNE is associated with poor disease outcomes 1. Etemadmoghadam, et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. Plos One, 2010. 2. Turner, et al. Cyclin E1 expression and palbocicl

  22. Slide 22: Highly selective and potent CDK2 inhibitors spare CDK anti-targets

    Slide 22: Highly selective and potent CDK2 inhibitors spare CDK anti-targets

    Our highly selective and potent CDK2 inhibitors spare CDK anti-targets Data presented at AACR 2021 Annual Meeting. 22 ENZYME ACTIVITY IC 50 (NM) Kinome S (10) CDK2 CDK1 CDK4 CDK6 CDK7 CDK9 BLU0298 0.045 2.6 233.6 377.4 275.2 6941.2 6115.1 BLU1954 0.055 0.2 110.1 114.5 190.6 3928.9 849.1 BLU2256 0.04

  23. Slide 23: Selective CDK2 inhibition leads to sustained anti-tumor activity

    Slide 23: Selective CDK2 inhibition leads to sustained anti-tumor activity

    Selective CDK2 inhibition leads to sustained anti-tumor activity in CCNE1-amplified in vivo models Data presented at AACR 2021 Annual Meeting. BID, twice daily. 23 Vehicle BLU2256 5 mg/kg BID Not for promotional use. Days 1600 0 0 1400 1200 1000 800 600 400 200 4 8 12 16 20 24 28 Dosing Tumor volume

  24. Slide 24: Multiple pipeline programs driving to planned clinical data disclosures in 2022

    Slide 24: Multiple pipeline programs driving to planned clinical data disclosures in 2022

    Multiple pipeline programs driving to planned clinical data disclosures in 2022 24 • Initiate Phase 1 trial of BLU-945 in Q2 2021 • Initiate Phase 1 trial of BLU-701 in 2H 2021 • Report preclinical combination data in 2H 2021 BLU-701 AND BLU-945 POTENTIAL FIRST- AND BEST-IN-CLASS 4G EGFRINHIBITORS •

  25. Slide 25: Rapidly expanding portfolio highlights precision therapy leadership

    Slide 25: Rapidly expanding portfolio highlights precision therapy leadership

    Rapidly expanding portfolio highlights precision therapy leadership 1. Unresectable or metastatic disease. 2. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 3. Approved in the U.S. for

  26. Slide 26: (Sbwuepriat’

    Slide 26: (Sbwuepriat’

    (Sbwuepriat’

Source: SEC EDGAR · 8-K filed Apr 12, 2021

More decks from Blueprint Medicines Corp